Skip to main content
. 2018 Feb 7;55(5):351–358. doi: 10.1136/jmedgenet-2017-104863

Figure 6.

Figure 6

Effect of antibody formation on lysoGb3 in men with classical Fabry disease. Linear mixed model of the change in lysoGb3 adjusted for lysoGb3 at baseline, stratified for enzyme replacement therapy (ERT) type and antibody status. The larger lines represent the predicted values at group level (at the mean lysoGb3 concentration of 105 nmol/L in these patients), the smaller lines represent the predicted values at individual patient level.